A publication referencing abaloparatide appeared on 2026-07-27 in the journal Frontiers in Aging. The article is titled "Aging-related metabolic dysregulation in osteoporosis: mechanisms and therapeutic strategies." It was indexed with PubMed ID 42577358. The publication is listed as a review addressing mechanisms and therapeutic strategies related to osteoporosis in the context of aging. No specific findings, data, or conclusions from the article were provided beyond its title and publication details. Abaloparatide is an approved compound, and its inclusion in this review reflects its relevance to the broader topic of osteoporosis treatment discussed in the piece. Readers should note that this brief reports only the existence and bibliographic details of the publication. No efficacy, safety, or outcome data from the article are described here. Those interested in the full scope of the review, including any discussion of abaloparatide's role in metabolic dysregulation or therapeutic strategy, should consult the original source directly. For additional background on abaloparatide, including its approved uses and general profile, readers can consult the compound overview.
Abaloparatide Cited in New Osteoporosis Review Published in Frontiers in Aging
See the full abaloparatide overview
Source: https://pubmed.ncbi.nlm.nih.gov/42577358/